Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

· WestVac Biopharma Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), covering 2024-07-25 to 2024-07-25. Get the full timeline:

Most recent: Clinical Trial Update: A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination [Phase 3]

See pricing